<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33645548</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>09</Month>
        <Day>20</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>02</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1558-8238</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>131</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Mar</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of clinical investigation</Title>
          <ISOAbbreviation>J Clin Invest</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e145186</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1172/JCI145186</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">145186</ELocationID>
        <Abstract>
          <AbstractText>Immune checkpoint inhibitors (ICIs) have transformed the treatment of various cancers, including malignancies once considered untreatable. These agents, however, are associated with inflammation and tissue damage in multiple organs. Myocarditis has emerged as a serious ICI-associated toxicity, because, while seemingly infrequent, it is often fulminant and lethal. The underlying basis of ICI-associated myocarditis is not completely understood. While the importance of T cells is clear, the inciting antigens, why they are recognized, and the mechanisms leading to cardiac cell injury remain poorly characterized. These issues underscore the need for basic and clinical studies to define pathogenesis, identify predictive biomarkers, improve diagnostic strategies, and develop effective treatments. An improved understanding of ICI-associated myocarditis will provide insights into the equilibrium between the immune and cardiovascular systems.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Moslehi</LastName>
            <ForeName>Javid</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiovascular Medicine and Division of Oncology, Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lichtman</LastName>
            <ForeName>Andrew H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharpe</LastName>
            <ForeName>Arlene H</ForeName>
            <Initials>AH</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Immunology and Blavatnik Institute, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Galluzzi</LastName>
            <ForeName>Lorenzo</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiation Oncology, Sandra and Edward Meyer Cancer Center, Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medical College, New York, New York, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Université de Paris, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kitsis</LastName>
            <ForeName>Richard N</ForeName>
            <Initials>RN</Initials>
            <AffiliationInfo>
              <Affiliation>Departments of Medicine and Cell Biology, Wilf Family Cardiovascular Research Institute, and Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 HL138475</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 AI056299</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL130861</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL141466</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R01 HL131862</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>P01 AI039671</GrantID>
            <Acronym>AI</Acronym>
            <Agency>NIAID NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Clin Invest</MedlineTA>
        <NlmUniqueID>7802877</NlmUniqueID>
        <ISSNLinking>0021-9738</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009205" MajorTopicYN="N">Myocarditis</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement><b>Conflict of interest:</b> JM has served on scientific advisory boards for Bristol Myers Squibb, Takeda, Deciphera, AstraZeneca, Nektar, Audentes Therapeutics, TripleGene, Boston Biomedical, ImmunoCore, Janssen, Myovant, Cytokinetics, and Amgen. AHS is on the scientific advisory boards for Surface Oncology, SQZ Biotech, Elstar Therapeutics, Elpiscience, Selecta, and Monopteros, consults for Novartis, and has research funding from Merck, Novartis, Roche, Ipsen, and Quark Ventures. AHS has patents/pending royalties from Roche and Novartis on intellectual property on the PD-1 pathway (patent 7,432,059 with royalties paid from Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Leica, Mayo Clinic, Dako, and Novartis; patent 7,722,868 with royalties paid from Roche, Merck, Bristol-Myers-Squibb, EMD-Serono, Boehringer-Ingelheim, AstraZeneca, Leica, Mayo Clinic, Dako, and Novartis; patents 8,652,465 and 9,457,080 licensed to Roche; patents 9,683,048, 9,815,898, 9,845,356, 10,202,454. and 10,457,733 licensed to Novartis; and patents 9,580,684, 9,988,452, and 10,370,446 issued to none). LG has received research funding from Lytix and Phosplatin, as well as consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation. RNK is cofounder and president of ASPIDA Therapeutics Inc. RNK has a patent (PCT/ US2018/021644) for small-molecule BAX inhibitors.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>1</Day>
          <Hour>9</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33645548</ArticleId>
        <ArticleId IdType="pmc">PMC7919710</ArticleId>
        <ArticleId IdType="doi">10.1172/JCI145186</ArticleId>
        <ArticleId IdType="pii">145186</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi: 10.1126/science.aar4060.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aar4060</ArticleId>
            <ArticleId IdType="pmc">PMC7391259</ArticleId>
            <ArticleId IdType="pubmed">29567705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, et al.  Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17(12):725–741. doi: 10.1038/s41571-020-0413-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-020-0413-z</ArticleId>
            <ArticleId IdType="pubmed">32760014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei SC, et al.  Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–1086. doi: 10.1158/2159-8290.CD-18-0367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-18-0367</ArticleId>
            <ArticleId IdType="pubmed">30115704</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol. 2020;20(2):75–76. doi: 10.1038/s41577-020-0275-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-0275-8</ArticleId>
            <ArticleId IdType="pubmed">31925406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalbasi A, Ribas A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat Rev Immunol. 2020;20(1):25–39. doi: 10.1038/s41577-019-0218-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-019-0218-4</ArticleId>
            <ArticleId IdType="pmc">PMC8499690</ArticleId>
            <ArticleId IdType="pubmed">31570880</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, et al.  The hallmarks of successful anticancer immunotherapy. Sci Transl Med. 2018;10(459):eaat7807.  doi: 10.1126/scitranslmed.aat7807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aat7807</ArticleId>
            <ArticleId IdType="pubmed">30232229</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, et al.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017. doi: 10.1056/NEJMoa1414428.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1414428</ArticleId>
            <ArticleId IdType="pmc">PMC5744258</ArticleId>
            <ArticleId IdType="pubmed">25891304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tang J, et al.  Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat Rev Drug Discov. 2018;17(12):854–855. doi: 10.1038/nrd.2018.210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd.2018.210</ArticleId>
            <ArticleId IdType="pubmed">30482962</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xin Yu J, et al.  Immuno-oncology drug development goes global. Nat Rev Drug Discov. 2019;18(12):899–900. doi: 10.1038/d41573-019-00167-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/d41573-019-00167-9</ArticleId>
            <ArticleId IdType="pubmed">31780841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Postow MA, et al.  Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158–168. doi: 10.1056/NEJMra1703481.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1703481</ArticleId>
            <ArticleId IdType="pubmed">29320654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, et al.  Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721–1728. doi: 10.1001/jamaoncol.2018.3923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2018.3923</ArticleId>
            <ArticleId IdType="pmc">PMC6440712</ArticleId>
            <ArticleId IdType="pubmed">30242316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu JR, et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res. 2019;115(5):854–868. doi: 10.1093/cvr/cvz026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvz026</ArticleId>
            <ArticleId IdType="pmc">PMC6452314</ArticleId>
            <ArticleId IdType="pubmed">30715219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, et al.  Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749–1755. doi: 10.1056/NEJMoa1609214.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1609214</ArticleId>
            <ArticleId IdType="pmc">PMC5247797</ArticleId>
            <ArticleId IdType="pubmed">27806233</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem JE, et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579–1589. doi: 10.1016/S1470-2045(18)30608-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30608-9</ArticleId>
            <ArticleId IdType="pmc">PMC6287923</ArticleId>
            <ArticleId IdType="pubmed">30442497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drobni ZD, et al.  Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299–2311. doi: 10.1161/CIRCULATIONAHA.120.049981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.049981</ArticleId>
            <ArticleId IdType="pmc">PMC7736526</ArticleId>
            <ArticleId IdType="pubmed">33003973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lichtman AH. The heart of the matter: protection of the myocardium from T cells. J Autoimmun. 2013;45:90–96. doi: 10.1016/j.jaut.2013.05.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaut.2013.05.004</ArticleId>
            <ArticleId IdType="pmc">PMC3783609</ArticleId>
            <ArticleId IdType="pubmed">23810579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stritesky GL, et al.  Selection of self-reactive T cells in the thymus. Annu Rev Immunol. 2012;30:95–114. doi: 10.1146/annurev-immunol-020711-075035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-020711-075035</ArticleId>
            <ArticleId IdType="pmc">PMC3518413</ArticleId>
            <ArticleId IdType="pubmed">22149933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klein L, et al.  Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see) Nat Rev Immunol. 2014;14(6):377–391. doi: 10.1038/nri3667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3667</ArticleId>
            <ArticleId IdType="pmc">PMC4757912</ArticleId>
            <ArticleId IdType="pubmed">24830344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singer A, et al.  Lineage fate and intense debate: myths, models and mechanisms of CD4- versus CD8-lineage choice. Nat Rev Immunol. 2008;8(10):788–801. doi: 10.1038/nri2416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2416</ArticleId>
            <ArticleId IdType="pmc">PMC2760737</ArticleId>
            <ArticleId IdType="pubmed">18802443</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carpenter AC, Bosselut R. Decision checkpoints in the thymus. Nat Immunol. 2010;11(8):666–673. doi: 10.1038/ni.1887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1887</ArticleId>
            <ArticleId IdType="pmc">PMC3388799</ArticleId>
            <ArticleId IdType="pubmed">20644572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grossman Z, Paul WE. Dynamic tuning of lymphocytes: physiological basis, mechanisms, and function. Annu Rev Immunol. 2015;33:677–713. doi: 10.1146/annurev-immunol-032712-100027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-032712-100027</ArticleId>
            <ArticleId IdType="pubmed">25665077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neefjes J, et al.  Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol. 2011;11(12):823–836. doi: 10.1038/nri3084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3084</ArticleId>
            <ArticleId IdType="pubmed">22076556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gay D, et al.  Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen. Nature. 1987;328(6131):626–629. doi: 10.1038/328626a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/328626a0</ArticleId>
            <ArticleId IdType="pubmed">3112582</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marusic-Galesic S, et al.  Development of CD4-CD8+ cytotoxic T cells requires interactions with class I MHC determinants. Nature. 1988;333(6169):180–183. doi: 10.1038/333180a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/333180a0</ArticleId>
            <ArticleId IdType="pubmed">3259290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13(4):227–242. doi: 10.1038/nri3405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3405</ArticleId>
            <ArticleId IdType="pmc">PMC3786574</ArticleId>
            <ArticleId IdType="pubmed">23470321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharpe AH. Mechanisms of costimulation. Immunol Rev. 2009;229(1):5–11. doi: 10.1111/j.1600-065X.2009.00784.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-065X.2009.00784.x</ArticleId>
            <ArticleId IdType="pmc">PMC2928676</ArticleId>
            <ArticleId IdType="pubmed">19426211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harding FA, et al.  CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature. 1992;356(6370):607–609. doi: 10.1038/356607a0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/356607a0</ArticleId>
            <ArticleId IdType="pubmed">1313950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lenschow DJ, et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science. 1992;257(5071):789–792. doi: 10.1126/science.1323143.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1323143</ArticleId>
            <ArticleId IdType="pubmed">1323143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amarante-Mendes GP, et al.  Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:2379. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6232773</ArticleId>
            <ArticleId IdType="pubmed">30459758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esensten JH, et al.  CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5):973–988. doi: 10.1016/j.immuni.2016.04.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.04.020</ArticleId>
            <ArticleId IdType="pmc">PMC4932896</ArticleId>
            <ArticleId IdType="pubmed">27192564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161–168. doi: 10.1016/j.immuni.2011.07.010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2011.07.010</ArticleId>
            <ArticleId IdType="pmc">PMC3303224</ArticleId>
            <ArticleId IdType="pubmed">21867926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schwartz RH. Historical overview of immunological tolerance. Cold Spring Harb Perspect Biol. 2012;4(4):a006908. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3312674</ArticleId>
            <ArticleId IdType="pubmed">22395097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301–305. doi: 10.1126/science.1071059.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1071059</ArticleId>
            <ArticleId IdType="pubmed">11951032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Palmer E. Negative selection—clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol. 2003;3(5):383–391. doi: 10.1038/nri1085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri1085</ArticleId>
            <ArticleId IdType="pubmed">12766760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spetz J, et al.  T cells and regulated cell death: kill or be killed. Int Rev Cell Mol Biol. 2019;342:27–71. doi: 10.1016/bs.ircmb.2018.07.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/bs.ircmb.2018.07.004</ArticleId>
            <ArticleId IdType="pmc">PMC7325157</ArticleId>
            <ArticleId IdType="pubmed">30635093</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schildberg FA, et al.  Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity. 2016;44(5):955–972. doi: 10.1016/j.immuni.2016.05.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.05.002</ArticleId>
            <ArticleId IdType="pmc">PMC4905708</ArticleId>
            <ArticleId IdType="pubmed">27192563</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jenkins MK, et al.  Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol. 1990;144(1):16–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2153162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asano M, et al.  Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J Exp Med. 1996;184(2):387–396. doi: 10.1084/jem.184.2.387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.184.2.387</ArticleId>
            <ArticleId IdType="pmc">PMC2192701</ArticleId>
            <ArticleId IdType="pubmed">8760792</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. doi: 10.1126/science.aaa8172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aaa8172</ArticleId>
            <ArticleId IdType="pubmed">25838373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Collins AV, et al.  The interaction properties of costimulatory molecules revisited. Immunity. 2002;17(2):201–210. doi: 10.1016/S1074-7613(02)00362-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1074-7613(02)00362-X</ArticleId>
            <ArticleId IdType="pubmed">12196291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelhardt JJ, et al.  CTLA-4 overexpression inhibits T cell responses through a CD28-B7-dependent mechanism. J Immunol. 2006;177(2):1052–1061. doi: 10.4049/jimmunol.177.2.1052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.177.2.1052</ArticleId>
            <ArticleId IdType="pubmed">16818761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linsley PS, et al.  Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med. 1992;176(6):1595–1604. doi: 10.1084/jem.176.6.1595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.176.6.1595</ArticleId>
            <ArticleId IdType="pmc">PMC2119471</ArticleId>
            <ArticleId IdType="pubmed">1334116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walunas TL, et al.  CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405–413. doi: 10.1016/1074-7613(94)90071-X.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/1074-7613(94)90071-X</ArticleId>
            <ArticleId IdType="pubmed">7882171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunner MC, et al.  CTLA-4-Mediated inhibition of early events of T cell proliferation. J Immunol. 1999;162(10):5813–5820.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10229815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linsley PS, et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. Immunity. 1994;1(9):793–801. doi: 10.1016/S1074-7613(94)80021-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1074-7613(94)80021-9</ArticleId>
            <ArticleId IdType="pubmed">7534620</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Merwe PA, et al.  CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med. 1997;185(3):393–403. doi: 10.1084/jem.185.3.393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.185.3.393</ArticleId>
            <ArticleId IdType="pmc">PMC2196039</ArticleId>
            <ArticleId IdType="pubmed">9053440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wing K, et al.  CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271–275. doi: 10.1126/science.1160062.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1160062</ArticleId>
            <ArticleId IdType="pubmed">18845758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wing JB, et al.  Human FOXP3+ regulatory T cell heterogeneity and function in autoimmunity and cancer. Immunity. 2019;50(2):302–316. doi: 10.1016/j.immuni.2019.01.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2019.01.020</ArticleId>
            <ArticleId IdType="pubmed">30784578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hori S, et al.  Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057–1061. doi: 10.1126/science.1079490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1079490</ArticleId>
            <ArticleId IdType="pubmed">12522256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tivol EA, et al.  Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995;3(5):541–547. doi: 10.1016/1074-7613(95)90125-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/1074-7613(95)90125-6</ArticleId>
            <ArticleId IdType="pubmed">7584144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waterhouse P, et al.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270(5238):985–988. doi: 10.1126/science.270.5238.985.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.270.5238.985</ArticleId>
            <ArticleId IdType="pubmed">7481803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuehn HS, et al.  Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–1627. doi: 10.1126/science.1255904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1255904</ArticleId>
            <ArticleId IdType="pmc">PMC4371526</ArticleId>
            <ArticleId IdType="pubmed">25213377</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubert D, et al.  Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nat Med. 2014;20(12):1410–1416. doi: 10.1038/nm.3746.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3746</ArticleId>
            <ArticleId IdType="pmc">PMC4668597</ArticleId>
            <ArticleId IdType="pubmed">25329329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Latchman Y, et al.  PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol. 2001;2(3):261–268. doi: 10.1038/85330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/85330</ArticleId>
            <ArticleId IdType="pubmed">11224527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi: 10.1038/nrc3239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc3239</ArticleId>
            <ArticleId IdType="pmc">PMC4856023</ArticleId>
            <ArticleId IdType="pubmed">22437870</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eppihimer MJ, et al.  Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells. Microcirculation. 2002;9(2):133–145. doi: 10.1080/713774061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/713774061</ArticleId>
            <ArticleId IdType="pmc">PMC3740166</ArticleId>
            <ArticleId IdType="pubmed">11932780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Greenwald RJ, et al.  The B7 family revisited. Annu Rev Immunol. 2005;23:515–548. doi: 10.1146/annurev.immunol.23.021704.115611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev.immunol.23.021704.115611</ArticleId>
            <ArticleId IdType="pubmed">15771580</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, et al.  PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A. 2001;98(24):13866–13871. doi: 10.1073/pnas.231486598.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.231486598</ArticleId>
            <ArticleId IdType="pmc">PMC61133</ArticleId>
            <ArticleId IdType="pubmed">11698646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimura H, et al.  Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11(2):141–151. doi: 10.1016/S1074-7613(00)80089-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1074-7613(00)80089-8</ArticleId>
            <ArticleId IdType="pubmed">10485649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waliany S, et al.  Immune checkpoint inhibitor cardiotoxicity: understanding basic mechanisms and clinical characteristics and finding a cure. Annu Rev Pharmacol Toxicol. 2020;61:113–134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32776859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Francisco LM, et al.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015–3029. doi: 10.1084/jem.20090847.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20090847</ArticleId>
            <ArticleId IdType="pmc">PMC2806460</ArticleId>
            <ArticleId IdType="pubmed">20008522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan CL, et al.  PD-1 restraint of regulatory T cell suppressive activity is critical for immune tolerance. J Exp Med. 2021;218(1):e20182232.  doi: 10.1084/jem.20182232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20182232</ArticleId>
            <ArticleId IdType="pmc">PMC7543091</ArticleId>
            <ArticleId IdType="pubmed">33045061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Triebel F, et al.  LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med. 1990;171(5):1393–1405. doi: 10.1084/jem.171.5.1393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.171.5.1393</ArticleId>
            <ArticleId IdType="pmc">PMC2187904</ArticleId>
            <ArticleId IdType="pubmed">1692078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anderson AC, et al.  Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi: 10.1016/j.immuni.2016.05.001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.05.001</ArticleId>
            <ArticleId IdType="pmc">PMC4942846</ArticleId>
            <ArticleId IdType="pubmed">27192565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Melero I, et al.  Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007;7(2):95–106. doi: 10.1038/nrc2051.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrc2051</ArticleId>
            <ArticleId IdType="pubmed">17251916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han X, Vesely MD. Stimulating T cells against cancer with agonist immunostimulatory monoclonal antibodies. Int Rev Cell Mol Biol. 2019;342:1–25. doi: 10.1016/bs.ircmb.2018.07.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/bs.ircmb.2018.07.003</ArticleId>
            <ArticleId IdType="pmc">PMC6487201</ArticleId>
            <ArticleId IdType="pubmed">30635089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fucikova J, et al.  TIM-3 dictates functional orientation of the immune infiltrate in ovarian cancer. Clin Cancer Res. 2019;25(15):4820–4831. doi: 10.1158/1078-0432.CCR-18-4175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-4175</ArticleId>
            <ArticleId IdType="pubmed">31076549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Andrews LP, et al.  Inhibitory receptors and ligands beyond PD-1, PD-L1, and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20(11):1425–1434. doi: 10.1038/s41590-019-0512-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-019-0512-0</ArticleId>
            <ArticleId IdType="pubmed">31611702</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koyama S, et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016;7:10501. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4757784</ArticleId>
            <ArticleId IdType="pubmed">26883990</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leach DR, et al.  Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–1736. doi: 10.1126/science.271.5256.1734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.271.5256.1734</ArticleId>
            <ArticleId IdType="pubmed">8596936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong H, et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8(8):793–800. doi: 10.1038/nm730.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm730</ArticleId>
            <ArticleId IdType="pubmed">12091876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwai Y, et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A. 2002;99(19):12293–12297. doi: 10.1073/pnas.192461099.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.192461099</ArticleId>
            <ArticleId IdType="pmc">PMC129438</ArticleId>
            <ArticleId IdType="pubmed">12218188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Juneja VR, et al.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J Exp Med. 2017;214(4):895–904. doi: 10.1084/jem.20160801.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20160801</ArticleId>
            <ArticleId IdType="pmc">PMC5379970</ArticleId>
            <ArticleId IdType="pubmed">28302645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirano F, et al.  Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005;65(3):1089–1096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15705911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375(18):1767–1778. doi: 10.1056/NEJMra1514296.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1514296</ArticleId>
            <ArticleId IdType="pmc">PMC5575761</ArticleId>
            <ArticleId IdType="pubmed">27806234</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hodi FS, et al.  Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi: 10.1056/NEJMoa1003466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1003466</ArticleId>
            <ArticleId IdType="pmc">PMC3549297</ArticleId>
            <ArticleId IdType="pubmed">20525992</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topalian SL, et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi: 10.1056/NEJMoa1200690.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200690</ArticleId>
            <ArticleId IdType="pmc">PMC3544539</ArticleId>
            <ArticleId IdType="pubmed">22658127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi: 10.1056/NEJMoa1200694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1200694</ArticleId>
            <ArticleId IdType="pmc">PMC3563263</ArticleId>
            <ArticleId IdType="pubmed">22658128</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robert C, et al.  Pembrolizumab vs ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. doi: 10.1056/NEJMoa1503093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1503093</ArticleId>
            <ArticleId IdType="pubmed">25891173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mangan BL, et al.  Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol. 2020;86(9):1778–1789. doi: 10.1111/bcp.14433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bcp.14433</ArticleId>
            <ArticleId IdType="pmc">PMC7444794</ArticleId>
            <ArticleId IdType="pubmed">32543711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, et al.  Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncol. 2020;21(8):e398–e404. doi: 10.1016/S1470-2045(20)30107-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(20)30107-8</ArticleId>
            <ArticleId IdType="pubmed">32758477</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, et al.  Immune checkpoint inhibitor toxicity in 2018. JAMA. 2018;320(16):1702–1703. doi: 10.1001/jama.2018.13995.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2018.13995</ArticleId>
            <ArticleId IdType="pubmed">30286224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Larkin J, et al.  Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi: 10.1056/NEJMoa1504030.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1504030</ArticleId>
            <ArticleId IdType="pmc">PMC5698905</ArticleId>
            <ArticleId IdType="pubmed">26027431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deutsch E, et al.  Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncol. 2019;20(8):e452–e463. doi: 10.1016/S1470-2045(19)30171-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(19)30171-8</ArticleId>
            <ArticleId IdType="pubmed">31364597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li W, et al.  Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol. 2015;66(10):1160–1178. doi: 10.1016/j.jacc.2015.07.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2015.07.025</ArticleId>
            <ArticleId IdType="pubmed">26337996</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bellinger AM, et al.  Cardio-oncology: how new targeted cancer therapies and precision medicine can inform cardiovascular discovery. Circulation. 2015;132(23):2248–2258. doi: 10.1161/CIRCULATIONAHA.115.010484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.010484</ArticleId>
            <ArticleId IdType="pmc">PMC4863699</ArticleId>
            <ArticleId IdType="pubmed">26644247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng CC, et al.  21st century cardio-oncology: identifying cardiac safety signals in the era of personalized medicine. JACC Basic Transl Sci. 2016;1(5):386–398. doi: 10.1016/j.jacbts.2016.05.008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacbts.2016.05.008</ArticleId>
            <ArticleId IdType="pmc">PMC5508213</ArticleId>
            <ArticleId IdType="pubmed">28713868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uraizee I, et al.  Reversible cardiomyopathy associated with sunitinib and sorafenib. N Engl J Med. 2011;365(17):1649–1650. doi: 10.1056/NEJMc1108849.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1108849</ArticleId>
            <ArticleId IdType="pubmed">22030001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petroni G, et al.  Immunomodulation by targeted anticancer agents. Cancer Cell. 2020;S1535–6108(20):30601–30602.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33338426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah KP, et al.  Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy. Cancer Immunol Res. 2020;8(7):851–855. doi: 10.1158/2326-6066.CIR-19-0986.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2326-6066.CIR-19-0986</ArticleId>
            <ArticleId IdType="pmc">PMC7334081</ArticleId>
            <ArticleId IdType="pubmed">32350001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eggermont AMM, et al.  Adjuvant pembrolizumab vs placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–1801. doi: 10.1056/NEJMoa1802357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1802357</ArticleId>
            <ArticleId IdType="pubmed">29658430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17(8):474–502. doi: 10.1038/s41569-020-0348-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41569-020-0348-1</ArticleId>
            <ArticleId IdType="pmc">PMC8782611</ArticleId>
            <ArticleId IdType="pubmed">32231332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moey MYY, et al.  Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis. Eur Respir J. 2020;55(6):2000038.  doi: 10.1183/13993003.00038-2020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/13993003.00038-2020</ArticleId>
            <ArticleId IdType="pubmed">32079644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vozy A, et al.  Increased reporting of fatal hepatitis associated with immune checkpoint inhibitors. Eur J Cancer. 2019;123:112–115. doi: 10.1016/j.ejca.2019.09.022.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejca.2019.09.022</ArticleId>
            <ArticleId IdType="pubmed">31678768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson DB, et al.  Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J Immunother Cancer. 2019;7(1):134.  doi: 10.1186/s40425-019-0617-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0617-x</ArticleId>
            <ArticleId IdType="pmc">PMC6530194</ArticleId>
            <ArticleId IdType="pubmed">31118078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moslehi JJ, et al.  Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6668330</ArticleId>
            <ArticleId IdType="pubmed">29536852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmood SS, et al.  Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755–1764. doi: 10.1016/j.jacc.2018.02.037.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2018.02.037</ArticleId>
            <ArticleId IdType="pmc">PMC6196725</ArticleId>
            <ArticleId IdType="pubmed">29567210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Escudier M, et al.  Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085–2087. doi: 10.1161/CIRCULATIONAHA.117.030571.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.030571</ArticleId>
            <ArticleId IdType="pubmed">29158217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ederhy S, et al.  Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors. JACC Cardiovasc Imaging. 2018;11(8):1187–1190. doi: 10.1016/j.jcmg.2017.11.036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcmg.2017.11.036</ArticleId>
            <ArticleId IdType="pubmed">29550317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anquetil C, et al.  Immune checkpoint inhibitor-associated myositis: expanding the spectrum of cardiac complications of the immunotherapy revolution. Circulation. 2018;138(7):743–745. doi: 10.1161/CIRCULATIONAHA.118.035898.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.118.035898</ArticleId>
            <ArticleId IdType="pubmed">30359135</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allenbach Y, et al.  Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev. 2020;19(8):102586.  doi: 10.1016/j.autrev.2020.102586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.autrev.2020.102586</ArticleId>
            <ArticleId IdType="pubmed">32535094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Norwood TG, et al.  Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017;5(1):91.  doi: 10.1186/s40425-017-0296-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0296-4</ArticleId>
            <ArticleId IdType="pmc">PMC5697345</ArticleId>
            <ArticleId IdType="pubmed">29157297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moslehi J. The cardiovascular perils of cancer survivorship. N Engl J Med. 2013;368(11):1055–1056. doi: 10.1056/NEJMe1215300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMe1215300</ArticleId>
            <ArticleId IdType="pubmed">23484833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonaca MP, et al.  Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. Circulation. 2019;140(2):80–91.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6779326</ArticleId>
            <ArticleId IdType="pubmed">31390169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caforio ALP, et al.  Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease. Eur Heart J. 2017;38(35):2649–2662. doi: 10.1093/eurheartj/ehx321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/eurheartj/ehx321</ArticleId>
            <ArticleId IdType="pubmed">28655210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moslehi JJ, et al.  Fulminant myocarditis: evolving diagnosis, evolving biology, evolving prognosis. J Am Coll Cardiol. 2019;74(3):312–314. doi: 10.1016/j.jacc.2019.05.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2019.05.026</ArticleId>
            <ArticleId IdType="pubmed">31319913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aretz HT, et al.  Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol. 1987;1(1):3–14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3455232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baughman KL. Diagnosis of myocarditis: death of Dallas criteria. Circulation. 2006;113(4):593–595. doi: 10.1161/CIRCULATIONAHA.105.589663.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.105.589663</ArticleId>
            <ArticleId IdType="pubmed">16449736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Groarke JD, et al.  Cancer-drug discovery and cardiovascular surveillance. N Engl J Med. 2013;369(19):1779–1781. doi: 10.1056/NEJMp1313140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMp1313140</ArticleId>
            <ArticleId IdType="pubmed">24180496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee Chuy K, et al.  Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: the memorial sloan kettering cancer center experience. Oncologist. 2019;24(5):e196–e197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6516118</ArticleId>
            <ArticleId IdType="pubmed">30910868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang DY, et al.  Cardiovascular toxicities associated with cancer immunotherapies. Curr Cardiol Rep. 2017;19(3):21.  doi: 10.1007/s11886-017-0835-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11886-017-0835-0</ArticleId>
            <ArticleId IdType="pubmed">28220466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375(15):1457–1467. doi: 10.1056/NEJMra1100265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1100265</ArticleId>
            <ArticleId IdType="pubmed">27732808</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neilan TG, et al.  Myocarditis associated with immune checkpoint inhibitors: an expert consensus on data gaps and a call to action. Oncologist. 2018;23(8):874–878. doi: 10.1634/theoncologist.2018-0157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0157</ArticleId>
            <ArticleId IdType="pmc">PMC6156187</ArticleId>
            <ArticleId IdType="pubmed">29802220</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23(8):879–886. doi: 10.1634/theoncologist.2018-0130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1634/theoncologist.2018-0130</ArticleId>
            <ArticleId IdType="pmc">PMC6156176</ArticleId>
            <ArticleId IdType="pubmed">29802219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brahmer JR, et al.  Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(17):1714–1768. doi: 10.1200/JCO.2017.77.6385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.77.6385</ArticleId>
            <ArticleId IdType="pmc">PMC6481621</ArticleId>
            <ArticleId IdType="pubmed">29442540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puzanov I, et al.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5(1):95.  doi: 10.1186/s40425-017-0300-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-017-0300-z</ArticleId>
            <ArticleId IdType="pmc">PMC5697162</ArticleId>
            <ArticleId IdType="pubmed">29162153</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang L, et al.  Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141(24):2031–2034. doi: 10.1161/CIRCULATIONAHA.119.044703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.119.044703</ArticleId>
            <ArticleId IdType="pmc">PMC7301778</ArticleId>
            <ArticleId IdType="pubmed">32539614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mahmood SS, et al.  Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: a case report. Gynecol Oncol Rep. 2018;25:74–77. doi: 10.1016/j.gore.2018.05.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gore.2018.05.014</ArticleId>
            <ArticleId IdType="pmc">PMC6005798</ArticleId>
            <ArticleId IdType="pubmed">29922709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arangalage D, et al.  Survival after fulminant myocarditis induced by immune-checkpoint inhibitors. Ann Intern Med. 2017;167(9):683–684. doi: 10.7326/L17-0396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7326/L17-0396</ArticleId>
            <ArticleId IdType="pubmed">28869988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Esfahani K, et al.  Alemtuzumab for immune-related myocarditis due to PD-1 therapy. N Engl J Med. 2019;380(24):2375–2376. doi: 10.1056/NEJMc1903064.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1903064</ArticleId>
            <ArticleId IdType="pubmed">31189042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem JE, et al.  Abatacept for severe immune checkpoint inhibitor-associated myocarditis. N Engl J Med. 2019;380(24):2377–2379. doi: 10.1056/NEJMc1901677.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1901677</ArticleId>
            <ArticleId IdType="pubmed">31189043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tay RY, et al.  Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. Br J Cancer. 2017;117(7):921–924. doi: 10.1038/bjc.2017.253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2017.253</ArticleId>
            <ArticleId IdType="pmc">PMC5625667</ArticleId>
            <ArticleId IdType="pubmed">28797029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geraud A, et al.  Clinical pharmacology and interplay of immune checkpoint agents: a yin-yang balance. Annu Rev Pharmacol Toxicol. 2021;61:85–112. doi: 10.1146/annurev-pharmtox-022820-093805.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-pharmtox-022820-093805</ArticleId>
            <ArticleId IdType="pubmed">32871087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linsley PS, et al.  Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science. 1992;257(5071):792–795. doi: 10.1126/science.1496399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1496399</ArticleId>
            <ArticleId IdType="pubmed">1496399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei SC, et al.  A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov.  doi: 10.1158/2159-8290.CD-20-0856. [published online December 1, 2020].</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-20-0856</ArticleId>
            <ArticleId IdType="pmc">PMC8041233</ArticleId>
            <ArticleId IdType="pubmed">33257470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kociol RD, et al.  Recognition and initial management of fulminant myocarditis: a scientific statement from the American Heart Association. Circulation. 2020;141(6):e69–e92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31902242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoos A. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov. 2016;15(4):235–247. doi: 10.1038/nrd.2015.35.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd.2015.35</ArticleId>
            <ArticleId IdType="pubmed">26965203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73. doi: 10.1056/NEJMra1706169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMra1706169</ArticleId>
            <ArticleId IdType="pmc">PMC7433347</ArticleId>
            <ArticleId IdType="pubmed">29972754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jackson HJ, et al.  Driving CAR T-cells forward. Nat Rev Clin Oncol. 2016;13(6):370–383. doi: 10.1038/nrclinonc.2016.36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2016.36</ArticleId>
            <ArticleId IdType="pmc">PMC5529102</ArticleId>
            <ArticleId IdType="pubmed">27000958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fielding AK, et al.  Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950. doi: 10.1182/blood-2006-05-018192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2006-05-018192</ArticleId>
            <ArticleId IdType="pubmed">17032921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grupp SA, et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518. doi: 10.1056/NEJMoa1215134.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1215134</ArticleId>
            <ArticleId IdType="pmc">PMC4058440</ArticleId>
            <ArticleId IdType="pubmed">23527958</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maude SL, et al.  Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–448. doi: 10.1056/NEJMoa1709866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1709866</ArticleId>
            <ArticleId IdType="pmc">PMC5996391</ArticleId>
            <ArticleId IdType="pubmed">29385370</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linette GP, et al.  Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013;122(6):863–871. doi: 10.1182/blood-2013-03-490565.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2013-03-490565</ArticleId>
            <ArticleId IdType="pmc">PMC3743463</ArticleId>
            <ArticleId IdType="pubmed">23770775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cameron BJ, et al.  Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med. 2013;5(197):197ra03. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6002776</ArticleId>
            <ArticleId IdType="pubmed">23926201</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pollack A, et al.  Viral myocarditis—diagnosis, treatment options, and current controversies. Nat Rev Cardiol. 2015;12(11):670–680. doi: 10.1038/nrcardio.2015.108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrcardio.2015.108</ArticleId>
            <ArticleId IdType="pubmed">26194549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grabie N, et al.  T cell checkpoint regulators in the heart. Cardiovasc Res. 2019;115(5):869–877. doi: 10.1093/cvr/cvz025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvz025</ArticleId>
            <ArticleId IdType="pmc">PMC6452292</ArticleId>
            <ArticleId IdType="pubmed">30721928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Swirski FK, Nahrendorf M. Cardioimmunology: the immune system in cardiac homeostasis and disease. Nat Rev Immunol. 2018;18(12):733–744. doi: 10.1038/s41577-018-0065-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-018-0065-8</ArticleId>
            <ArticleId IdType="pubmed">30228378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grabie N, et al.  Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation. 2007;116(18):2062–2071. doi: 10.1161/CIRCULATIONAHA.107.709360.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.107.709360</ArticleId>
            <ArticleId IdType="pubmed">17938288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kania G, et al.  Innate signaling promotes formation of regulatory nitric oxide-producing dendritic cells limiting T-cell expansion in experimental autoimmune myocarditis. Circulation. 2013;127(23):2285–2294. doi: 10.1161/CIRCULATIONAHA.112.000434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.112.000434</ArticleId>
            <ArticleId IdType="pubmed">23671208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nishimura H, et al.  Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319–322. doi: 10.1126/science.291.5502.319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.291.5502.319</ArticleId>
            <ArticleId IdType="pubmed">11209085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, et al.  Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477–1483. doi: 10.1038/nm955.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm955</ArticleId>
            <ArticleId IdType="pubmed">14595408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarrio ML, et al.  PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis. J Immunol. 2012;188(10):4876–4884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3345066</ArticleId>
            <ArticleId IdType="pubmed">22491251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keir ME, et al.  Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006;203(4):883–895. doi: 10.1084/jem.20051776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20051776</ArticleId>
            <ArticleId IdType="pmc">PMC2118286</ArticleId>
            <ArticleId IdType="pubmed">16606670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gil-Cruz C, et al.  Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. Science. 2019;366(6467):881–886. doi: 10.1126/science.aav3487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aav3487</ArticleId>
            <ArticleId IdType="pubmed">31727837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nindl V, et al.  Cooperation of Th1 and Th17 cells determines transition from autoimmune myocarditis to dilated cardiomyopathy. Eur J Immunol. 2012;42(9):2311–2321. doi: 10.1002/eji.201142209.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/eji.201142209</ArticleId>
            <ArticleId IdType="pubmed">22730043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucas JA, et al.  Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice. J Immunol. 2008;181(4):2513–2521. doi: 10.4049/jimmunol.181.4.2513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.181.4.2513</ArticleId>
            <ArticleId IdType="pmc">PMC2587295</ArticleId>
            <ArticleId IdType="pubmed">18684942</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, et al.  PD-1 deficiency results in the development of fatal myocarditis in MRL mice. Int Immunol. 2010;22(6):443–452. doi: 10.1093/intimm/dxq026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/intimm/dxq026</ArticleId>
            <ArticleId IdType="pubmed">20410257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okazaki T, et al.  PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice. J Exp Med. 2011;208(2):395–407. doi: 10.1084/jem.20100466.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20100466</ArticleId>
            <ArticleId IdType="pmc">PMC3039848</ArticleId>
            <ArticleId IdType="pubmed">21300912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cihakova D, Rose NR. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol. 2008;99:95–114. doi: 10.1016/S0065-2776(08)00604-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0065-2776(08)00604-4</ArticleId>
            <ArticleId IdType="pubmed">19117533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neu N, et al.  Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. 1987;139(11):3630–3636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">3680946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smith SC, Allen PM. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol. 1991;147(7):2141–2147.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1918949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Donermeyer DL, et al.  Myocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart. J Exp Med. 1995;182(5):1291–1300. doi: 10.1084/jem.182.5.1291.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.182.5.1291</ArticleId>
            <ArticleId IdType="pmc">PMC2192215</ArticleId>
            <ArticleId IdType="pubmed">7595200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galvin JE, et al.  Induction of myocarditis and valvulitis in lewis rats by different epitopes of cardiac myosin and its implications in rheumatic carditis. Am J Pathol. 2002;160(1):297–306. doi: 10.1016/S0002-9440(10)64373-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0002-9440(10)64373-8</ArticleId>
            <ArticleId IdType="pmc">PMC1867128</ArticleId>
            <ArticleId IdType="pubmed">11786423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kodama M, et al.  A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction. Clin Immunol Immunopathol. 1990;57(2):250–262. doi: 10.1016/0090-1229(90)90039-S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0090-1229(90)90039-S</ArticleId>
            <ArticleId IdType="pubmed">2208806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Myers JM, et al.  Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight. 2016;1(9):85851. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4924810</ArticleId>
            <ArticleId IdType="pubmed">27366791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, et al.  Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006;177(11):8234–8240. doi: 10.4049/jimmunol.177.11.8234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.177.11.8234</ArticleId>
            <ArticleId IdType="pubmed">17114501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stavrakis S, et al.  Activating autoantibodies to the beta-1 adrenergic and M2 muscarinic receptors facilitate atrial fibrillation in patients with Graves’ hyperthyroidism. J Am Coll Cardiol. 2009;54(14):1309–1316. doi: 10.1016/j.jacc.2009.07.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2009.07.015</ArticleId>
            <ArticleId IdType="pmc">PMC2801559</ArticleId>
            <ArticleId IdType="pubmed">19778674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mascaro-Blanco A, et al.  Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies. Autoimmunity. 2008;41(6):442–453. doi: 10.1080/08916930802031579.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/08916930802031579</ArticleId>
            <ArticleId IdType="pmc">PMC3108569</ArticleId>
            <ArticleId IdType="pubmed">18781470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, et al.  Cutting edge: cardiac myosin activates innate immune responses through TLRs. J Immunol. 2009;183(1):27–31. doi: 10.4049/jimmunol.0800861.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0800861</ArticleId>
            <ArticleId IdType="pmc">PMC2720835</ArticleId>
            <ArticleId IdType="pubmed">19535635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krisher K, Cunningham MW. Myosin: a link between streptococci and heart. Science. 1985;227(4685):413–415. doi: 10.1126/science.2578225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.2578225</ArticleId>
            <ArticleId IdType="pubmed">2578225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cunningham MW, et al.  Cytotoxic and viral neutralizing antibodies crossreact with streptococcal M protein, enteroviruses, and human cardiac myosin. Proc Natl Acad Sci U S A. 1992;89(4):1320–1324. doi: 10.1073/pnas.89.4.1320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.89.4.1320</ArticleId>
            <ArticleId IdType="pmc">PMC48441</ArticleId>
            <ArticleId IdType="pubmed">1311095</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huber SA, et al.  Alterations in major histocompatibility complex association of myocarditis induced by coxsackievirus B3 mutants selected with monoclonal antibodies to group A streptococci. Proc Natl Acad Sci U S A. 1994;91(12):5543–5547. doi: 10.1073/pnas.91.12.5543.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.91.12.5543</ArticleId>
            <ArticleId IdType="pmc">PMC44032</ArticleId>
            <ArticleId IdType="pubmed">8202524</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massilamany C, et al.  Relevance of molecular mimicry in the mediation of infectious myocarditis. J Cardiovasc Transl Res. 2014;7(2):165–171. doi: 10.1007/s12265-013-9519-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12265-013-9519-3</ArticleId>
            <ArticleId IdType="pmc">PMC3943813</ArticleId>
            <ArticleId IdType="pubmed">24263348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morgan RA, et al.  Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013;36(2):133–151. doi: 10.1097/CJI.0b013e3182829903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CJI.0b013e3182829903</ArticleId>
            <ArticleId IdType="pmc">PMC3581823</ArticleId>
            <ArticleId IdType="pubmed">23377668</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao Y, et al.  High-affinity TCRs generated by phage display provide CD4+ T cells with the ability to recognize and kill tumor cell lines. J Immunol. 2007;179(9):5845–5854. doi: 10.4049/jimmunol.179.9.5845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.179.9.5845</ArticleId>
            <ArticleId IdType="pmc">PMC2140228</ArticleId>
            <ArticleId IdType="pubmed">17947658</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv H, et al.  Impaired thymic tolerance to α-myosin directs autoimmunity to the heart in mice and humans. J Clin Invest. 2011;121(4):1561–1573. doi: 10.1172/JCI44583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI44583</ArticleId>
            <ArticleId IdType="pmc">PMC3069776</ArticleId>
            <ArticleId IdType="pubmed">21436590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ammirati E, et al.  Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document. Circ Heart Fail. 2020;13(11):e007405. </Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7673642</ArticleId>
            <ArticleId IdType="pubmed">33176455</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Lostao L, et al.  How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21(22):5047–5056. doi: 10.1158/1078-0432.CCR-15-0685.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-0685</ArticleId>
            <ArticleId IdType="pubmed">26567364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Re DP, et al.  Fundamental mechanisms of regulated cell death and implications for heart disease. Physiol Rev. 2019;99(4):1765–1817. doi: 10.1152/physrev.00022.2018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1152/physrev.00022.2018</ArticleId>
            <ArticleId IdType="pmc">PMC6890986</ArticleId>
            <ArticleId IdType="pubmed">31364924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Galluzzi L, et al.  Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25(3):486–541. doi: 10.1038/s41418-017-0012-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-017-0012-4</ArticleId>
            <ArticleId IdType="pmc">PMC5864239</ArticleId>
            <ArticleId IdType="pubmed">29362479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Voskoboinik I, et al.  Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15(6):388–400. doi: 10.1038/nri3839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3839</ArticleId>
            <ArticleId IdType="pubmed">25998963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, et al.  CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. Nature. 2019;569(7755):270–274. doi: 10.1038/s41586-019-1170-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1170-y</ArticleId>
            <ArticleId IdType="pmc">PMC6533917</ArticleId>
            <ArticleId IdType="pubmed">31043744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reddy J, et al.  Autoimmunity in viral myocarditis. Curr Opin Rheumatol. 2013;25(4):502–508. doi: 10.1097/BOR.0b013e3283620036.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/BOR.0b013e3283620036</ArticleId>
            <ArticleId IdType="pubmed">23656709</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alvi RM, et al.  Cardiovascular events among adults treated with chimeric antigen receptor T-Cells (CAR-T) J Am Coll Cardiol. 2019;74(25):3099–3108. doi: 10.1016/j.jacc.2019.10.038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2019.10.038</ArticleId>
            <ArticleId IdType="pmc">PMC6938409</ArticleId>
            <ArticleId IdType="pubmed">31856966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salem JE, et al.  Cardiac events associated with chimeric antigen receptor T-cells (CAR-T): a VigiBase perspective. J Am Coll Cardiol. 2020;75(19):2521–2523. doi: 10.1016/j.jacc.2020.02.070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jacc.2020.02.070</ArticleId>
            <ArticleId IdType="pubmed">32408984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ganatra S, et al.  Chimeric antigen receptor T-cell therapy-associated cardiomyopathy in patients with refractory or relapsed non-Hodgkin lymphoma. Circulation. 2020;142(17):1687–1690. doi: 10.1161/CIRCULATIONAHA.120.048100.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048100</ArticleId>
            <ArticleId IdType="pubmed">33104402</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lefebvre B, et al.  Cardiovascular effects of CAR T cell therapy: a retrospective study. JACC CardioOncol. 2020;2(2):193–203. doi: 10.1016/j.jaccao.2020.04.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaccao.2020.04.012</ArticleId>
            <ArticleId IdType="pmc">PMC7413146</ArticleId>
            <ArticleId IdType="pubmed">32776016</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
